Take Homes in Lung Cancer

Take Homes in Lung Cancer

Source:

Healio Interview; Robert N, et al. Abstract 9004. Presented at: ASCO Annual Meeting (virtual meeting); June 4-8, 2021.

Disclosures: Disclosure: Pennell reports serving in a consulting or advisory role for Bristol Myer Squibb, Genentech and Janssen.
June 24, 2021
1 min watch
Save

VIDEO: Biomarker testing critically important for patients with metastatic lung cancer

Source:

Healio Interview; Robert N, et al. Abstract 9004. Presented at: ASCO Annual Meeting (virtual meeting); June 4-8, 2021.

Disclosures: Disclosure: Pennell reports serving in a consulting or advisory role for Bristol Myer Squibb, Genentech and Janssen.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

In this video, Nathan A. Pennell, MD, PhD, highlighted a presentation from the virtual ASCO Annual Meeting, which looked at trends in molecular testing among patients with metastatic lung cancer in the U.S.

When restricting biomarker testing to EGFR, ALK, BRAF, ROS and PDL-1, the findings showed that less than half of those eligible are receiving molecular testing and even less are receiving next-generation sequencing.

“We actually have highly effective treatments that can help patients with metastatic lung cancer live for years with minimal side effects,” Pennell, medical oncologist at the Cleveland Clinic and associate professor medical oncology at the Cleveland Clinic Lerner College, said. “But you have to test for them.”